UNSPSC 51402401: Azacyclonol

This classification denotes an anxiolytic with the molecular formula C18H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2MMR990PEM, chemically known as 4-piperidinemethanol, alpha,alpha-diphenyl- but generally known as azacyclonol, which bears US NIH Compound Identifier 15723. Azacyclonol most often comes in base and hydrochloride forms. European Medicines Agency schedules Azacyclonol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05628MIG.

UNSPSC 51402401 Azacyclonol is a Commodity code that captures pharmaceutical products state and local governments procure for health and safety initiatives, though recent solicitations tagged under this code reflect a broader range of pharmaceutical and drug-related procurement rather than azacyclonol specifically. State and local health departments, county health systems, and cooperative purchasing alliances are the primary issuing bodies, supported by health and human services commissions conducting market research for pharmacy benefit programs. The work being solicited includes naloxone acquisition for opioid emergency response, generic and over-the-counter pharmaceutical distribution through established wholesaler networks, and exploratory contracting for direct-to-manufacturer prescription programs. Vendors must comply with FDA requirements, cGMP certification, Drug Supply Chain Security Act standards, and maintain appropriate insurance coverage; some procurements require E-Verify compliance and drug-free workplace certification.

Recent activity spans Florida, Minnesota, and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026, due July 26, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year term with one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendors to work through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson as authorized wholesalers, with evaluation weighted heavily to price competitiveness (75 percent) and a two-year initial contract term. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 as a preliminary market-intelligence effort to assess vendor capacity for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and wholesaler arrangements, suggesting forthcoming formal procurement activity in that state.